Article
Oncology
Bin Wang, Yang Dong, Xuyao Yu, Fengtong Li, Jingsheng Wang, Huaming Chen, Zeqian Niu, Yongchun Song, Zhiyong Yuan, Zhen Tao
Summary: SBRT treatment at a dose of 56 Gy/6-8f is beneficial for UCLC patients, and smaller PTV is associated with better outcomes.
FRONTIERS IN ONCOLOGY
(2022)
Review
Immunology
Yao Xiao, Hongqing Zhuang
Summary: The combination of SRT and immunotherapy has shown good clinical efficacy in the treatment of lung cancer. SRT activates the immune system, promotes antigen-antibody response, and induces tumor cell apoptosis. However, dose fractionation and time have an impact on SRT combined immunotherapy, and many issues still require further research.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Joe Y. Chang, Reza J. Mehran, Lei Feng, Vivek Verma, Zhongxing Liao, James W. Welsh, Steven H. Lin, Michael S. O'Reilly, Melenda D. Jeter, Peter A. Balter, Stephen E. McRae, Donald Berry, John Heymach, Jack A. Roth
Summary: Long-term results from the revised STARS trial showed that survival after SABR is non-inferior to VATS L-MLND for operable stage IA NSCLC. SABR remains promising for such cases, with multidisciplinary management strongly recommended.
Article
Oncology
Nagore Garcia-Exposito, Ricard Ramos, Valentin Navarro-Perez, Kevin Molina, Maria Dolores Arnaiz, Susana Padrones, Jose Carlos Ruffinelli, Cristina Santos, Ferran Guedea, Arturo Navarro-Martin
Summary: Colorectal cancer is a common malignancy and lung and liver are the most common sites of metastasis. Surgery has been the traditional treatment for lung metastases, but stereotactic body radiotherapy (SBRT) is becoming increasingly favored. This study aimed to compare the local control rates of SBRT and surgery in patients with colorectal cancer lung metastases.
Article
Oncology
Yuhei Miyasaka, Shuichiro Komatsu, Takanori Abe, Nobuteru Kubo, Naoko Okano, Kei Shibuya, Katsuyuki Shirai, Hidemasa Kawamura, Jun-ichi Saitoh, Takeshi Ebara, Tatsuya Ohno
Summary: The study compared oncologic outcomes after CIRT and SBRT for early-stage NSCLC and found that CIRT showed superior overall survival and local control compared to SBRT. These results were validated by propensity score-adjusted analyses, demonstrating a positive efficacy profile of CIRT in the management of early-stage NSCLC.
Article
Oncology
Guillaume Virbel, David G. Cox, Anne Olland, Pierre-Emmanuel Falcoz, Clara Le Fevre, Roland Schott, Delphine Antoni, Georges Noel
Summary: Stereotactic body radiotherapy (SBRT) with a 60-Gy schedule in 8 fractions is an effective and well-tolerated treatment for patients with lung oligometastases from any solid primary tumor. It provides favorable clinical outcomes in terms of local control, progression-free survival, overall survival, and toxicity.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Shuri Aoki, Hiroshi Onishi, Masataka Karube, Naoyoshi Yamamoto, Hideomi Yamashita, Yoshiyuki Shioyama, Yasuo Matsumoto, Yukinori Matsuo, Akifumi Miyakawa, Haruo Matsushita, Hitoshi Ishikawa
Summary: This retrospective study aimed to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) and carbon ion radiotherapy (CIRT) in elderly patients with non-small-cell lung cancer (NSCLC) using Japanese multicenter data. The study found that SBRT and CIRT showed similar survival and local control rates in elderly patients, but CIRT was associated with a lower incidence of radiation pneumonitis.
Review
Oncology
Guillaume Virbel, Clara Le Fevre, Georges Noel, Delphine Antoni
Summary: Stereotactic body radiation therapy (SBRT) is an effective and safe treatment for lung metastases, particularly in oligometastatic patients with localized disease involving one to three organs. This review summarized the recent progress and evaluation results of radiotherapy for pulmonary metastasis in the past five years.
Editorial Material
Oncology
Ryan Fecteau, W. Robert Lee
Summary: Patients with nonmetastatic, high-risk prostate cancer have a higher likelihood of dying from causes unrelated to their cancer. Identifying patients at greater risk from competing risks is crucial for treatment decision-making.
Article
Oncology
Xuanchu Ge, Mingshan Yang, Tengxiang Li, Tonghai Liu, Xiangyu Gao, Qingtao Qiu, Yong Yin
Summary: This study compared different algorithms for dose calculation in complex radiotherapy scenarios and found that the FSPB_LS algorithm showed better dose consistency with the MC algorithm compared to the traditional FSPB algorithm. It also demonstrated improved accuracy in terms of dose parameters for the tumor target. However, significant dose deviations were observed in organ-at-risk parameters for CLC with both the FSPB_LS and MC algorithms.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Xiaoli Liu, Alexander Chi
Summary: Immunotherapy has revolutionized the treatment of metastatic NSCLC. Combining SBRT with immunotherapy is recognized as a promising treatment option. However, the most optimal approach for this combination remains controversial, and further exploration is needed.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Max Devine Devine, David J. Merriott, Hyunsoo J. No, Brianna Lau, Carmen Say, Christopher Yoo, Esther Yi, Ryan B. Ko, Joel W. Neal, Heather A. Wakelee, Millie Das, Billy W. Loo, Maximilian Diehn, Alex L. Chin, Lucas K. Vitzthum
Summary: The purpose of this study was to determine the rate of isolated hilar or mediastinal nodal recurrence (INR) in patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic ablative radiation therapy (SABR), and to describe patterns of care and treatment outcomes after salvage therapy. The results showed that INR occurred in approximately 10% of patients treated with SABR, and patients treated with salvage chemoradiation therapy had the highest survival rates.
PRACTICAL RADIATION ONCOLOGY
(2023)
Article
Oncology
Michele Aquilano, Mauro Loi, Luca Visani, Lorenzo Livi, Joost J. Nuyttens
Summary: This study investigated the impact of stereotactic body radiotherapy (SBRT) in patients with oligoprogression (OPD) from metastatic lung cancer. The results showed improved overall survival (OS) and local control (LC) after SBRT, although there was no statistically significant correlation. Therefore, SBRT is an effective treatment that can postpone the switch of systemic treatment when metastatic lesions grow slowly.
Article
Oncology
Ran Zhang, Yanling Guo, Yujie Yan, Yuanjun Liu, Yaoyao Zhu, Jingjing Kang, Fangjuan Li, Xiaojiang Sun, Ligang Xing, Yaping Xu
Summary: This study compared survival outcomes and toxicities between patients with clinically diagnosed early-stage lung cancer or biopsy-proven early-stage non-small cell lung cancer, demonstrating the rationality of stereotactic body radiotherapy (SBRT) as a local treatment option for early-stage lung cancer patients. The results showed no significant difference in terms of local control and overall survival between patients with pathologic results versus patients with no pathologic results after propensity score matching (PSM) analysis.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Fei Li, Hairong Jiang, Mingwei Bu, Xin Mu, Hongfu Zhao
Summary: Through literature analysis, it was found that the effectiveness of stereotactic body radiation therapy (SBRT) for early non-small cell lung cancer (NSCLC) is related to the central dose and average dose, while it is not significantly related to the nominal dose and peripheral dose. Therefore, more attention should be paid to the prescription of the central dose and average dose in the treatment.
RADIATION ONCOLOGY
(2022)
Article
Medicine, General & Internal
Hiromi Asada, Yoshimitsu Takahashi, Yuka Ono, Noriko Kishi, Yukinori Matsuo, Takashi Mizowaki, Takeo Nakayama
Summary: This study examined the emotional experiences of patients undergoing radiotherapy towards skin markings and found that many patients accepted them with resignation, while some felt uncomfortable. No factors were found to be significantly associated with the discomfort. Therefore, medical staff should strive to understand patients' emotional experiences and provide sufficient care and explanations.
PATIENT PREFERENCE AND ADHERENCE
(2022)
Article
Biology
Noriko Kishi, Yukinori Matsuo, Toshi Menju, Masatsugu Hamaji, Akiyoshi Nakakura, Hideki Hanazawa, Keiichi Takehana, Hiroshi Date, Takashi Mizowaki
Summary: This study conducted two propensity score-based analyses to compare three treatment modalities for stage I NSCLC. The results showed different treatment effects and identified patient subgroups with varying characteristics and risks, which can guide treatment decision-making for these patients.
JOURNAL OF RADIATION RESEARCH
(2022)
Article
Biology
Kazuihto Ueki, Yukinori Matsuo, Noriko Kishi, Masahiro Yoneyama, Hironori Yoshida, Yuichi Sakamori, Hiroaki Ozasa, Toyohiro Hirai, Takashi Mizowaki
Summary: This study found that elevated pretreatment pro-gastrin-releasing peptide (ProGRP) levels were associated with an increased risk of brain metastasis in LS-SCLC patients. Prophylactic cranial irradiation (PCI) may help reduce the risk of brain metastasis, particularly in patients with higher ProGRP levels. These results provide a reliable method for determining which LS-SCLC patients should undergo PCI.
JOURNAL OF RADIATION RESEARCH
(2022)
Article
Multidisciplinary Sciences
Noriko Kishi, Yukinori Matsuo, Hideki Hanazawa, Yusuke Iizuka, Takashi Mizowaki
Summary: Marital status is not associated with prognosis in patients receiving SBRT for early-stage NSCLC.
Article
Oncology
Yukinori Matsuo, Masahiro Hiraoka, Katsuyuki Karasawa, Masaki Kokubo, Takashi Sakamoto, Nobutaka Mukumoto, Mitsuhiro Nakamura, Satoshi Morita, Takashi Mizowaki
Summary: This study evaluated the safety and efficacy of dynamic tumor tracking-stereotactic body radiotherapy (DTT-SBRT) for lung tumors and found that DTT-SBRT achieved excellent local control with low incidences of severe toxicities in lung tumors with respiratory motion.
RADIOTHERAPY AND ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Keiichi Takehana, Ryo Sakamoto, Koji Fujimoto, Yukinori Matsuo, Naoki Nakajima, Akihiko Yoshizawa, Toshi Menju, Mitsuhiro Nakamura, Ryo Yamada, Takashi Mizowaki, Yuji Nakamoto
Summary: The present study developed a machine learning model to predict STAS using peritumoral radiomics features extracted from preoperative CT imaging. The results showed that the machine learning model based on radiomics features performed better than the conventional C/T ratio model in predicting STAS.
SCIENTIFIC REPORTS
(2022)
Article
Biology
Noriko Kishi, Yukinori Matsuo, Takashi Shintani, Masakazu Ogura, Takamasa Mitsuyoshi, Norio Araki, Kota Fujii, Setsuko Okumura, Kiyoshi Nakamatsu, Takahiro Kishi, Tomoko Atsuta, Takashi Sakamoto, Shuji Ohtsu, Tomohiro Katagiri, Masaru Narabayashi, Satsuki Fujishiro, Yusuke Iizuka, Hiroaki Ozasa, Toyohiro Hirai, Takashi Mizowaki
Summary: Chemoradiotherapy followed by consolidation durvalumab improves survival in patients with stage III non-small-cell lung cancer (NSCLC). The study compared recurrence patterns and survival rates between different treatment groups and found that consolidation durvalumab reduced locoregional recurrence and distant metastasis, leading to improved progression-free survival.
JOURNAL OF RADIATION RESEARCH
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Dejun Zhou, Mitsuhiro Nakamura, Nobutaka Mukumoto, Yukinori Matsuo, Takashi Mizowaki
Summary: The feasibility of a deep learning-based markerless real-time tumor tracking method was studied in lung cancer treatment. Ten patients treated with marker-implanted RTTT were included in the study. The results show that the proposed method is feasible and can accurately predict tumor position in lung cancer patients.
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS
(2023)
Article
Oncology
Yusuke Iizuka, Masahiro Hiraoka, Masaki Kokubo, Takashi Sakamoto, Katsuyuki Karasawa, Keiko Murofushi, Mitsuhiro Nakamura, Yukinori Matsuo, Satoshi Morita, Haruo Inokuchi, Takashi Mizowaki
Summary: This prospective multicenter phase II study evaluated the safety and efficacy of dynamic tumor tracking (DTT) stereotactic body radiotherapy (SBRT) with real-time monitoring of liver tumors using a gimbal-mounted system. The results showed that DTT-SBRT for liver tumors achieved excellent local control with an acceptable incidence of adverse events.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Yuta Sakurai, Shintaro Ambo, Mitsuhiro Nakamura, Hiraku Iramina, Yusuke Iizuka, Takamasa Mitsuyoshi, Yukinori Matsuo, Takashi Mizowaki
Summary: This study aimed to develop a prediction model for target positioning using diaphragm waveforms extracted from CBCT projection images. Four different regression-based PMs were trained and compared, and the results showed that PM(AS-4D-CBCT) outperformed PM4D-CBCT, proving the efficacy of the AS signal-based correction.
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Satoshi Kito, Nobutaka Mukumoto, Mitsuhiro Nakamura, Hiroaki Tanabe, Katsuyuki Karasawa, Masaki Kokubo, Takashi Sakamoto, Yusuke Iizuka, Michio Yoshimura, Yukinori Matsuo, Masahiro Hiraoka, Takashi Mizowaki
Summary: In this study, an asymmetric margin-calculation theory based on the Guide to the Expression of Uncertainty in Measurement (GUM) and motion probability distributions (MPD) was proposed. The margins for fiducial marker-based real-time tumor tracking (RTTT) in lung, liver, and pancreatic cancers were calculated and evaluated using Monte Carlo (MC) simulations. The results showed that the proposed margins were more accurate in terms of the median content rates compared to the margins calculated using van Herk's formula.
Article
Oncology
Hiroshi Onishi, Yoshiyuki Shioyama, Yasuo Matsumoto, Yukinori Matsuo, Akifumi Miyakawa, Hideomi Yamashita, Haruo Matsushita, Masahiko Aoki, Keiji Nihei, Tomoki Kimura, Hiromichi Ishiyama, Naoya Murakami, Kensei Nakata, Atsuya Takeda, Takashi Uno, Takuma Nomiya, Hiroshi Taguchi, Yuji Seo, Takafumi Komiyama, Kan Marino, Shinichi Aoki, Masaki Matsuda, Tomoko Akita, Masahide Saito
Summary: This study provides real-world evidence on the usefulness of stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) patients, compared to surgery. The results show that SBRT can effectively delay local progression and improve 3-year overall survival rate in medically operable patients. This evidence is important for shared decision-making, especially for older patients.
Article
Oncology
Shuri Aoki, Hiroshi Onishi, Masataka Karube, Naoyoshi Yamamoto, Hideomi Yamashita, Yoshiyuki Shioyama, Yasuo Matsumoto, Yukinori Matsuo, Akifumi Miyakawa, Haruo Matsushita, Hitoshi Ishikawa
Summary: This retrospective study aimed to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) and carbon ion radiotherapy (CIRT) in elderly patients with non-small-cell lung cancer (NSCLC) using Japanese multicenter data. The study found that SBRT and CIRT showed similar survival and local control rates in elderly patients, but CIRT was associated with a lower incidence of radiation pneumonitis.
Article
Oncology
Yukinori Matsuo
Summary: Stereotactic body radiotherapy (SBRT) is an effective alternative therapy for hepatocellular carcinoma (HCC) when standard treatments are not suitable. It has the potential to improve prognosis of HCC by achieving high local control rates. However, further research is needed to determine optimal use of SBRT in combination with other treatments and the evaluation of post-SBRT imaging.
Article
Biology
Hideaki Hirashima, Mitsuhiro Nakamura, Kiyonao Nakamura, Yukinori Matsuo, Takashi Mizowaki
Summary: The study evaluated the application of different types of dose calculation algorithms (AAA, CC, AXB, and PMC) in spine SBRT. The results showed that the doses calculated by AXB and PMC were consistent with the measurements from bone-equivalent phantom, while AAA and CC overestimated the doses. For spine SBRT plans, PMC, AAA, and CC overestimated the near minimum and maximum doses of the target and organs at risk compared to AXB. However, the mean dose difference was within an acceptable range.
JOURNAL OF RADIATION RESEARCH
(2023)
Article
Oncology
Vijaya R. Bhatt, Christopher Wichman, Thuy T. Koll, Alfred L. Fisher, Tanya M. Wildes, Ann Berger, James O. Armitage, Sarah A. Holstein, Lori J. Maness, Krishna Gundabolu
Summary: A study on older adults with AML receiving chemotherapy showed significant comorbidity burden and functional impairments at baseline, but cognitive and physical function improvements or stability, as well as improved depression scores, were observed in a high proportion of patients at three months post-treatment, indicating success of treatment.
JOURNAL OF GERIATRIC ONCOLOGY
(2024)
Correction
Oncology
Darren J. Walsh, Laura J. Sahm, Michelle O'Driscoll, Bronagh Bolger, Hitam Ameen, Michelle Hannan, Caitriona Goggin, Anne M. Horgan
JOURNAL OF GERIATRIC ONCOLOGY
(2024)
Article
Oncology
Eva Futtrup Maksten, Lasse Hjort Jakobsen, Boris Modrau, Hilde Jensvoll, Kristian Hay Kragholm, Judit Meszaros Jorgensen, Michael Roost Clausen, Robert Schou Pedersen, Andriette Dessau-Arp, Thomas Stauffer Larsen, Christian Bjorn Poulsen, Anne Ortved Gang, Peter Brown, Tarec C. El-Galaly, Marianne Tang Severinsen
Summary: The risk of developing dementia is not increased after lymphoma treatment among patients.
JOURNAL OF GERIATRIC ONCOLOGY
(2024)
Review
Oncology
P. A. L. Nelleke Seghers, Marije E. Hamaker, Shane O'Hanlon, Johanneke E. A. Portielje, Hans Wildiers, Pierre Soubeyran, Annemarie Coolbrandt, Siri Rostoft
Summary: This study identified a core set of symptoms to monitor in older patients with multimorbidity treated for cancer. These symptoms include those related to cancer, treatment side effects, functional decline, and destabilization of comorbidities. The results provide a basis for guiding symptom monitoring during cancer treatment.
JOURNAL OF GERIATRIC ONCOLOGY
(2024)
